SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Spotify Technology SA engages in the provision of digital music services. It operates through the Premium and Ad-Supported segments. The Premium segment provides subscribers with online and offline streaming access of music and podcasts on computers, tablets, and mobile devices. The Ad-Supported segment offers users with limited on-demand online access of music and unlimited online access of podcasts on computers, tablets, and mobile and smart devices. The company was founded by Daniel Ek and Martin Lorentzon on December 27, 2006 and is headquartered in Luxembourg.

Spotify Technology S.A.

Spotify is trending sharply higher following a strong earnings report that highlighted record user growth, expanding margins, and the success of its Wrapped campaign, sparking community debate over its transition from a pure growth story to a high-margin cash generator. Many users are pointing to impressive premium subscriber increases and improved profitability as reasons for the stock's significant bounce from its recent lows, viewing it as a major turning point.

The Charles Schwab Corp. is a savings and loan holding company, which engages in the provision of wealth management, securities brokerage, banking, asset management, custody, and financial advisory services. It operates through the Investor Services and Advisor Services segments. The Investor Services segment includes retail brokerage, investment advisory, and banking and trust services to individual investors, retirement plan and business services, as well as other corporate brokerage services, to businesses and employees. The Advisor Services segment provides custodial, trading, banking and trust, and support services to independent registered investment advisors, independent retirement advisors, and recordkeepers. The company was founded by Charles Robert Schwab in 1986 and is headquartered in Westlake, TX.

Charles Schwab Corp.

Charles Schwab is trending amidst widespread user frustration over persistent platform outages and trading restrictions on its ThinkorSwim and mobile apps, leading many to consider alternative brokers, even as the company reports strong financial performance, including a substantial share buyback and strategic acquisitions into private markets.

Churchill Capital Corp. X is a blank check company, which was created for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. The company was founded by Michael Klein on January 4, 2024 and is headquartered in New York, NY.

Churchill Capital Corp X - Ordinary Shares - Class A

Churchill Capital Corp X 

The imminent merger vote for Churchill Capital Corp X with Infleqtion, solidified by SEC approval and a clear timeline to trade as INFQ, is fueling significant investor interest. The community widely views Infleqtion as an undervalued leader in quantum technology, citing its robust government and industry partnerships, including with NASA and NVIDIA, and its superior neutral-atom computing, setting the stage for a potential re-rating against its peers.

Fermi, Inc. engages in the development of energy infrastructure. It intends to develop an energy and data center development campus to support the needs of to-be-built AI infrastructure. The company was founded by Rick Perry, Toby Neugebauer and Griffin Perry on January 10, 2025 and is headquartered in Amrillo, TX.

Fermi Inc

Fermi LLC

Fermi is trending due to a significant stock drop after a key potential tenant terminated a $150 million funding agreement for its Project Matador data center, despite management indicating ongoing negotiations and plans to accelerate other client deals. The community is actively debating whether this presents a 

Datadog, Inc. engages in the development of a monitoring and analytics platform for developers, information technology operations teams and business users. Its platform integrates and automates infrastructure monitoring, application performance monitoring and log management to provide real-time observability of its customers' entire technology stack. The company was founded by Olivier Pomel and Alexis Lê-Quôc on June 4, 2010 and is headquartered in New York, NY.

Datadog Inc - Ordinary Shares - Class A

Datadog Inc

Datadog is trending as its recent robust earnings beat and impressive high-value client additions are sparking optimism that this could signal a broader recovery for the beleaguered software sector, with many highlighting DDOG's critical role in AI infrastructure.

TeraWulf, Inc. owns and operates fully integrated environmentally clean bitcoin mining facilities in the United States. TeraWulf will generate domestically produced bitcoin powered by nuclear, hydro and solar energy. The company was founded by Paul Prager and Nazar Khan on February 8, 2021 and is headquartered in Easton, MD.

TeraWulf Inc

TeraWulf is trending after Morgan Stanley initiated coverage with an "Overweight" rating and a $37 price target, fueling optimism for its strategic pivot to high-performance computing and data center infrastructure. The community is actively discussing the company's strong power assets and expansion plans, with many anticipating a significant short squeeze.

Jumia Technologies AG engages in the provision of logistic services. It operates a pan-African e-commerce platform. It operates through the following geographical segments: West Africa, North Africa, East and South Africa, Europe, United Arab Emirates, and Others. The company was founded by Jeremy Hodara, Sacha Poignonnec, Peter Allerstorfer, Manuel Koser, Tunde Kehinde, and Raphael Afaedor in 2012 and is headquartered in Berlin, Germany.

Jumia Technologies Ag - ADR

Jumia Technologies is trending after its Q4 earnings report, which, despite an initial sell-off, highlighted strong revenue and GMV growth along with a substantial reduction in cash burn. The community is actively discussing this progress towards profitability by late 2026, viewing the dip as a buying opportunity in the promising African e-commerce market.

Evommune, Inc. is a clinical-stage biotechnology company. It engages in the development of medicines for inflammatory diseases. The company was founded by Luis C. Pena, Eugene Andrew Bauer, and Hans Hofland in 2020 and is headquartered in Palo Alto, CA.

Evommune Inc.

Evommune Inc

Evommune (EVMN) is experiencing significant upward momentum after announcing positive top-line data from its Phase 2a trial for EVO301 in moderate-to-severe atopic dermatitis, which met its primary efficacy and safety endpoints. The community is actively discussing strong price targets and potential for a short squeeze, though some caution about the company's valuation and debt for a biotech at this clinical stage.

Paramount Skydance Corp. is a next-generation global media and entertainment company that engages in providing content creation and distribution services. It operates through the following business segments: Studios, Direct-to-Consumer, and TV Media. Its portfolio unites brands including Paramount Pictures, Paramount Television, CBS, CBS News, Nickelodeon, MTV, BET, Comedy Central, Showtime, Paramount Plus, Pluto TV, and Skydance’s Animation, Film, Television, Interactive/Games, and Sports divisions. The company was founded on June 3, 2024 and is headquartered in New York, NY.

Paramount Skydance Corp. - Ordinary Shares - Class B

Paramount Skydance is trending due to its sweetened bid for Warner Bros. Discovery, which aims to de-risk the acquisition by covering debt and breakup fees amidst growing regulatory scrutiny for Netflix's competing offer, while the community actively discusses the strong subscriber growth from its recent UFC event.

Nektar Therapeutics is a biotechnology company, which engages in the discovery and development of novel therapies which selectively modulate the immune system to treat autoimmune disorders. It also focuses on immunology and unparalleled expertise in polymer chemistry to create one-of-a-kind, highly-selective medicines with optimal therapeutic benefit. The company was founded in 1990 and is headquartered in San Francisco, CA.

Nektar Therapeutics

Nektar Therapeutics is surging after releasing robust 52-week maintenance data for its atopic dermatitis drug, Rezpeg, showcasing durable efficacy and a clean safety profile. The community is actively discussing the drug's strong competitive positioning, which is further bolstered by recent Nobel Prize recognition validating Treg-based therapies, fueling significant upside potential and buyout speculation.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Wall Street Analysts Predict a 65.75% Upside in Aldeyra Therapeutics (ALDX): Here's  What You Should Know

The consensus price target hints at a 65.8% upside potential for Aldeyra Therapeutics (ALDX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Are Medical Stocks Lagging  Aldeyra Therapeutics (ALDX) This Year?

Here is how Aldeyra Therapeutics, Inc. (ALDX) and ANI Pharmaceuticals (ANIP) have performed compared to their sector so far this year.

PFG Investments LLC Reduces Stock Position in Aldeyra Therapeutics, Inc. $ALDX

PFG Investments LLC cut its stake in Aldeyra Therapeutics, Inc. (NASDAQ:ALDX - Free Report) by 74.3% in the third quarter, according to its most recent Form 13F filing with the Securities & Exchange...

Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) Short Interest Update

Aldeyra Therapeutics, Inc. (NASDAQ:ALDX - Get Free Report) saw a significant decline in short interest during the month of December. As of December 31st, there was short interest totaling 4,951,552...

Aldeyra Therapeutics (NASDAQ:ALDX) Shares Cross Above Fifty Day Moving Average - Time to Sell?

Aldeyra Therapeutics (NASDAQ:ALDX) Stock Crosses Above 50-Day Moving Average - Here's Why...

Aldeyra Therapeutics (NASDAQ:ALDX) Stock Crosses Above Fifty Day Moving Average - Should You Sell?

Aldeyra Therapeutics (NASDAQ:ALDX) Share Price Crosses Above 50 Day Moving Average - What's Next...

Aldeyra Therapeutics Target of Unusually Large Options Trading (NASDAQ:ALDX)

Aldeyra Therapeutics, Inc. (NASDAQ:ALDX - Get Free Report) saw some unusual options trading activity on Tuesday. Investors bought 12,807 call options on the stock. This is an increase of 1,592...

<ul class="summary-bullets"><li>The FDA delayed its decision on the dry eye drug Reproxalap without raising new issues.</li><li>The FDA pushed the PDUFA deadline to March 16, 2026, after requesting a clinical study report already reviewed under an earlier filing.</li><li>Regulatory progress continued, with the FDA sharing a draft label and outlining next steps.</li></ul>Aldeyra Therapeutics shares jumped on Tuesday, heading for their best day in more than eight months, after the U.S. Food and Drug Administration (FDA) extended its review of the company’s dry eye drug without flagging any new issues.The stock rose 31% to hit $5.22 at the time of writing.<h2 class="st-heading-2">FDA Timeline</h2>Aldeyra Therapeutics said the FDA has pushed back its decision deadline on Reproxalap, the company’s dry eye drug, to March 16, 2026. The deadline, known as the Prescription Drug User Fee Act target action date, had previously been set for Dec. 16.The extension follows a Dec. 12 meeting between the FDA and the company, during which the agency requested submission of a Clinical Study Report for a dry eye disease field trial. Aldeyra said the report was submitted to the NDA on the same day and was classified by the FDA as a major amendment, triggering the three-month extension.<h2 class="st-heading-2">Scope Of The FDA Request</h2>The company said the FDA made no other requests at the December meeting and did not identify any additional issues with the NDA review. The Clinical Study Report had already been reviewed by the FDA under the drug’s Investigational New Drug file.Aldeyra also said safety data from the field trial had been submitted earlier, in August, at the FDA’s request during the NDA review process.The field trial, for which top-line results were announced in May, did not meet its primary endpoint of improving dry eye symptoms compared with a vehicle control. The company said the trial was supportive of the activity of the drug relative to the vehicle and had been discussed with the FDA before the NDA submission.<h2 class="st-heading-2">Labeling Progress&nbsp;</h2>Earlier this month, the FDA shared a draft of the proposed label for the dry eye drug with Aldeyra, and the company said it has submitted a response. According to Aldeyra, the FDA indicated that if no major deficiencies are identified during the extended review period, the agency plans to communicate proposed labeling requests and any anticipated postmarketing requirements by Feb. 16, 2026.Aldeyra said the NDA was originally submitted on June 16, and was accepted for review as a complete class 2 response in July.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment for Aldeyra was ‘extremely bullish’ amid ‘extremely high’ message volume.<figure class="image"><img style="aspect-ratio:972/136;" src="https://news.stocktwits-cdn.com/aldx_ss_png_1199f19110.webp" alt="aldx ss.png" width="972" height="136"><figcaption>ALDX sentiment and message volume as of December 16| Source: Stocktwits</figcaption></figure>One bullish user expects the stock to “keep rising during the day.”<stembedurl>https://stocktwits.com/MUBSN/message/639307502</stembedurl>Another user said, “Abbvie buy this bad boy out!”<stembedurl>https://stocktwits.com/GhostLegend/message/639301686</stembedurl><a href="https://stocktwits.com/symbol/ALDX">Aldeyra’s stock</a> has risen 4% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Aldeyra Therapeutics logo is seen displayed on the screen of a tablet. (Photo Illustration by Sheldon Cooper/SOPA Images/LightRocket via Getty Images)

Why Is Aldeyra Therapeutics Stock Surging After FDA Delayed Its Dry Eye Drug Decision?

The FDA delayed its decision on the dry eye drug Reproxalap to March 2026 without raising new issues, while review and labeling discussions continued.

Equity

683 Capital Management LLC Has $4.14 Million Stake in Aldeyra Therapeutics, Inc. $ALDX

683 Capital Management LLC grew its position in Aldeyra Therapeutics, Inc. (NASDAQ:ALDX - Free Report) by 126.9% during the second quarter, according to the company in its most recent 13F filing with...

Aldeyra Therapeutics, Inc. $ALDX Shares Sold by Kennedy Capital Management LLC

Kennedy Capital Management LLC lessened its position in Aldeyra Therapeutics, Inc. (NASDAQ:ALDX - Free Report) by 44.3% in the second quarter, according to the company in its most recent Form 13F...

Aldeyra Therapeutics, Inc. is a biotechnology company, which engages in research and development activities with related general business planning, including raising capital. It engages in the discovery of therapies designed to treat immune-mediated diseases. The company was founded by Thomas A. Jordan and John E. Dowling on August 13, 2004 and is headquartered in Lexington, MA.

Fiscal Period	Estimated	Reported	Surprise	Result
Q4 '25	-$0.16	--	--	N/A
Q3 '25	-$0.13	--	--	N/A
Q2 '25	-$0.19	-$0.16	14.29%	BEAT
Q1 '25	-$0.27	--	--	N/A
Q4 '24	-$0.26	--	--	N/A

ALDX
Aldeyra Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Upcoming Earnings: Q4 '25

Historical Earnings

Latest ALDX News

ALDXAldeyra Therapeutics Inc